Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer.

Puisset, Florent; Mseddi, Mourad; Mourey, Loïc; Pouessel, Damien; Blanchet, Benoit; Chatelut, Etienne; Chevreau, Christine

Puisset, Florent; Mseddi, Mourad; Mourey, Loïc; Pouessel, Damien; Blanchet, Benoit; Chatelut, Etienne; Chevreau, Christine.

Afiliação

Puisset F; Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.
Mseddi M; CRCT, Cancer Research Center of Toulouse, Inserm U1037, Université Paul Sabatier, 31037 Toulouse, France.
Mourey L; Department of Pharmacokinetics and Pharmacochemistry, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, CARPEM, 75014 Paris, France.
Pouessel D; Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.
Blanchet B; Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.
Chatelut E; Department of Pharmacokinetics and Pharmacochemistry, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, CARPEM, 75014 Paris, France.
Chevreau C; UMR8038 CNRS, U1268 INSERM, Faculté de Pharmacie, Université Paris Cité, PRES Sorbonne Paris Cité, CARPEM, 75006 Paris, France.

Cancers (Basel) ; 15(1)2023 Jan 03.

Article em En | MEDLINE | ID: mdl-36612311

Palavras-chave

renal cancer; therapeutic drug monitoring; tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google